Reversal of lipid accumulation and gene expression was achieved by treatment of hiPSC-Hep with obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist and clinical candidate for NASH. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.